Celcuity Inc. 2025 Annual Report: Key Points for Investors

Overview

Celcuity Inc. (Nasdaq: CELC) has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report provides comprehensive updates on the company’s business operations, financial status, and risk profile. Celcuity operates within the medical laboratories sector and is engaged in the development and commercialization of pharmaceutical products, most notably gedatolisib, under an exclusive global license from Pfizer Inc.

Key Points from the Annual Report

• Celcuity remains a pre-commercial stage company, with no pharmaceutical products yet launched. The company has yet to generate revenue or profit from product sales, and continues to invest heavily in research, clinical trials, and commercialization preparations.
• Exclusive Global License with Pfizer for Gedatolisib: Celcuity holds exclusive global development and commercialization rights for gedatolisib, a PI3K/mTOR inhibitor targeted for cancer treatments. The company expresses confidence in its ability to capitalize on this agreement, but also notes financial obligations to Pfizer, including potential future payments.
• Financial Position and Capital Requirements: Celcuity’s ability to raise additional capital remains a critical factor. The company warns that failure to secure funding on acceptable terms could limit its progress or halt commercialization efforts. Recent financing activities have resulted in dilution of current shareholders and could lead to further dilution or share price declines.
• Market Capitalization and Share Structure: As of June 30, 2025, the aggregate market value of voting and non-voting common equity held by non-affiliates was approximately \$457.5 million, based on a closing share price of \$13.35. As of March 17, 2026, there were 48,336,675 shares of common stock outstanding.
• Risks and Uncertainties: The report includes an extensive summary of risk factors that could materially affect the share value:
  • Celcuity has not yet commercialized a pharmaceutical product, raising uncertainty about future revenue.
  • Inability to raise capital may limit drug development and commercialization.
  • Financing activities could dilute ownership and impact share price.
  • Dependence on key personnel and potential difficulty attracting talent.
  • Exposure to trade policy changes, tariffs, and regulatory shifts.
  • Indebtedness and liabilities may constrain cash flow and increase operational risk.
  • Competition from other pharmaceutical companies is significant.
  • Regulatory approval processes for products are lengthy, uncertain, and costly.
  • Potential challenges in scaling production and commercializing products, including hiring a qualified sales force.
• Forward-Looking Statements: The company outlines its expectations regarding revenue, business development activities, collaborations, reimbursement timelines, use of proceeds from financing, capital availability, and adequacy of cash to fund operations. These statements are subject to numerous risks and uncertainties.

Important Shareholder Considerations

• Celcuity’s future share price is highly sensitive to clinical progress, regulatory approvals, and financing capabilities.
• Any delays or setbacks in clinical trials, inability to raise capital, or negative changes in trade/regulatory policies could materially impact the company’s valuation and shareholder returns.
• Significant dilution risk remains due to ongoing financing needs.
• Competitive landscape and regulatory hurdles pose ongoing challenges.
• The exclusive Pfizer license is an asset, but also an obligation, with potential milestone payments and royalties affecting future cash flows.
• Shareholders should closely monitor the company’s announcements regarding clinical trial data, regulatory milestones, and financing activities, as these are likely to move the share price.

Potential Price-Sensitive Information

The report does not announce new clinical data or regulatory milestones, but reiterates the company’s pre-commercial status, ongoing capital requirements, and substantial risks. These factors are material for investors and may impact share value, especially if future developments are negative or if the company struggles to raise additional funds. The market capitalization and share count updates provide context for dilution risk and valuation.

Summary Table of Contents

• Business Overview
• Risk Factors
• Unresolved Staff Comments
• Cybersecurity
• Properties
• Legal Proceedings
• Mine Safety Disclosures
• Market for Common Equity
• Management’s Discussion and Analysis
• Financial Statements
• Controls and Procedures
• Executive Compensation
• Security Ownership
• Related Transactions
• Principal Accountant Fees
• Exhibits and Schedules
• Form 10-K Summary
• Signatures

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full Annual Report, consider all risk factors, and consult their financial advisors before making any investment decisions. Forward-looking statements are subject to change and actual results may differ materially from expectations.

View Celcuity Inc. Historical chart here